These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11081540)

  • 21. [New therapeutic possibilities in chronic hepatitis C].
    Criblez DH
    Praxis (Bern 1994); 2000 Mar; 89(11):450-3. PubMed ID: 10758732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C.
    Tinè F; Graviano D; Giannuoli G; Madonia S; Malizia G; Patti S; Fasola S; Cottone M; D'Amico G;
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1113-23. PubMed ID: 20848397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon-induced vitiligo in hepatitis C patients: a case series.
    Hamadah I; Binamer Y; Sanai FM; Abdo AA; Alajlan A
    Int J Dermatol; 2010 Jul; 49(7):829-33. PubMed ID: 20618507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pericarditis due to interferon-alpha therapy during treatment for chronic hepatitis C.
    Gressens B; Gohy P
    Acta Gastroenterol Belg; 2004; 67(3):301-2. PubMed ID: 15587340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
    Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
    Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Thyrotoxicosis due to long-term therapy with interferon alpha in the patient with mixed chronic active hepatitis B and C].
    Vortel J; Bures J; Rejchrt S; Zivný P; Palicka V
    Vnitr Lek; 1999 May; 45(5):301-4. PubMed ID: 15641255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C.
    Nouri K; Busso M; Machler BC
    Cutis; 1997 Dec; 60(6):289-90. PubMed ID: 9426968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Onset of type 1 diabetes mellitus during combination therapy of chronic hepatitis C with interferon-alpha and ribavirin].
    Christensen UB; Krogsgaard K
    Ugeskr Laeger; 2004 Mar; 166(11):1024-5. PubMed ID: 15049242
    [No Abstract]   [Full Text] [Related]  

  • 29. Diffuse cutaneous eruption due to interferon alfa and ribavirin treatment of chronic hepatitis C.
    Savk E; Uslu G; Karaoğlu AO; Sendur N; Karaman G
    J Eur Acad Dermatol Venereol; 2005 May; 19(3):396-8. PubMed ID: 15857485
    [No Abstract]   [Full Text] [Related]  

  • 30. The adjuvant role of thyroxine in the treatment of chronic hepatitis C infection.
    Tran HA; Ianna EA; Jones TL; Reeves GE
    QJM; 2012 Jul; 105(7):683-7. PubMed ID: 21690180
    [No Abstract]   [Full Text] [Related]  

  • 31. Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C.
    Kasahara A; Hiraide A; Tomita N; Iwahashi H; Imagawa A; Ohguro N; Yamamoto S; Mita E; Hayashi N
    J Gastroenterol; 2004 Nov; 39(11):1106-9. PubMed ID: 15580406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse effects of peg-Interferon and Ribavirin combined antiviral treatment in a Romanian hepatitis C virus infected cohort.
    Predescu O; Streba LA; Irimia E; Streba L; Mogoantă L
    Rom J Morphol Embryol; 2012; 53(3):497-502. PubMed ID: 23010773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treating viral hepatitis C: efficacy, side effects, and complications.
    Manns MP; Wedemeyer H; Cornberg M
    Gut; 2006 Sep; 55(9):1350-9. PubMed ID: 16905701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C virus infection, interferon α and lupus; a curious combination.
    Auñón-Rubio P; Hernández-Martínez E; Sevillano-Prieto A; Morales-Ruiz E
    Nefrologia; 2014; 34(4):534-6. PubMed ID: 25036072
    [No Abstract]   [Full Text] [Related]  

  • 35. Interferon-α induced psoriatic arthritis and autoimmune hemolytic anemia during chronic hepatitis C treatment.
    Oliveira TL; Caetano AZ; Belem JM; Klemz BC; Pinheiro MM
    Acta Reumatol Port; 2014; 39(4):327-30. PubMed ID: 25341062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pulmonary sarcoidosis--a rare complication of interferon treatment for chronic hepatitis C].
    Pellová A; Pella J; Schréter I; Somos A; Kristian P; Boom A
    Klin Mikrobiol Infekc Lek; 2006 Oct; 12(5):200-2. PubMed ID: 17080355
    [No Abstract]   [Full Text] [Related]  

  • 37. Acute reversible rhabdomyolysis during interferon alpha2B therapy for hepatitis C.
    Gabrielli M; Santarelli L; Serricchio M; Leo D; Pola P; Gasbarrini A
    Am J Gastroenterol; 2003 Apr; 98(4):940. PubMed ID: 12738487
    [No Abstract]   [Full Text] [Related]  

  • 38. Parkinsonism in patients with chronic hepatitis C treated with interferon-alpha2b: a report of two cases.
    Kajihara M; Montagnese S; Khanna P; Amodio P; Schapira AH; Dusheiko GM; Morgan MY
    Eur J Gastroenterol Hepatol; 2010 May; 22(5):628-31. PubMed ID: 20075741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should routine screening for celiac disease be considered before starting interferon/ribavirin treatment in patients affected by chronic hepatitis C or not?
    Nejad MR; Alavian SM
    Bratisl Lek Listy; 2012; 113(4):251. PubMed ID: 22502761
    [No Abstract]   [Full Text] [Related]  

  • 40. Guess what! Tinea manus during interferon-alpha therapy for chronic hepatitis C.
    Koga T; Shimizu A; Kubota Y; Nakayama J; Sohda T
    Eur J Dermatol; 2000; 10(7):565-6. PubMed ID: 11056434
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.